Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (10940)	11/10/1997 10:06:00 AM
From: CYBERKEN	Read Replies (1) \| Respond to of 32384

Many of the newly-invented "molecular" drugs have not been around long enough to find out if there are long-term side effects-and, if so, what they are. It appears to be the nature of most of these drugs that side effects would be greatly limited vis-a-vis currently available medicines. That, and the vastly increased effectiveness, is the basis of the theory that the biotech sector will dominate the health care market over the next several decades. Specifically relating to side effects: Even if more are discovered than expected, the 3rd, 4th, 5th generation of the drugs under development would most likely limit them further, and/or, other newly developed drugs which would limit them would be developed to be prescribed along with them. Nothing new here-and potential long-term side effects still create a risk factor in biotech investing.